| Literature DB >> 32560180 |
Mario Rivera-Izquierdo1,2,3, María Del Carmen Valero-Ubierna1, Silvia Martínez-Diz1, Miguel Ángel Fernández-García1, Divina Tatiana Martín-Romero1, Francisco Maldonado-Rodríguez1, María Rosa Sánchez-Pérez4, Luis Miguel Martín-delosReyes2,5, Virginia Martínez-Ruiz2,3,5, Pablo Lardelli-Claret2,3,5, Eladio Jiménez-Mejías2,3,4,5.
Abstract
The novel coronavirus disease (COVID-19) outbreak has quickly spread around the world, with Spain being one of the most severely affected countries. Healthcare professionals are an important risk group given their exposure. The aims of this study were to determine the prevalence of symptoms, main concerns as patients, preventive behaviours of healthcare professionals, and the different temporal outcomes associated with the negativization of PCR results. A total of 238 professionals were analysed and follow-up was conducted from 11 March to 21 April 2020 through clinical records, in-depth surveys, and telephone interviews. Symptoms, concerns, and preventive measures were documented, and temporal outcomes (start and end of symptoms, first positive PCR, and negativization of PCR) were analysed through survival analyses. A high prevalence of gastrointestinal symptoms (especially in women and older professionals), fever, cough, and fatigue were reported. The main concern was contagion in the work and home environment. Professionals (especially men) reported low use of face masks before the pandemic. Our analysis indicates that the median times for the negativization of PCR testing to confirm the resolution of infection is 15 days after the end of symptoms, or 25 days after the first positive PCR test. Our results suggest that these times are longer for women and for professionals aged ≥55 years, therefore follow-up strategies should be optimized in light of both variables. This is the first study we are aware of to report factors associated with the time to negativization of PCR results. We present the first rigorous estimates of time outcomes and hope that these data can be valuable to continue feeding the prediction models that are currently being developed. Similar studies are required to corroborate our results.Entities:
Keywords: COVID; PCR; SARS-CoV-2; follow-up; healthcare; negativization; professionals
Mesh:
Year: 2020 PMID: 32560180 PMCID: PMC7345067 DOI: 10.3390/ijerph17124305
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Distribution of baseline characteristics in the whole sample and according to sex and age, and proportion of hospitalizations in each category.
| Variable | Total | Males | Females | <55 Years | ≥55 Years | Hospitalized |
|---|---|---|---|---|---|---|
| Total | 76 (100) | 23 (30.3) | 53 (69.7) | 53 (69.7) | 23 (30.3) | 11 (14.5) |
|
| ||||||
| Medical | 24 (31.6) | 13 (56.5) | 11 (20.7) | 20 (37.7) | 4 (17.4) | 5 (20.8) |
| Nursing | 39 (51.3) | 6 (26.1) | 33 (62.3) | 25 (47.2) | 14 (60.9) | 4 (10.3) |
| Others | 13 (17.1) | 4 (17.4) | 9 (17.0) | 8 (15.1) | 5 (21.7) | 2 (50.0) |
|
| ||||||
| Physicians | 15 (19.7) | 7 (30.4) | 8 (15.1) | 11 (20.8) | 4 (17.4) | 4 (26.7) |
| Doctors in training | 8 (10.5) | 5 (21.7) | 3 (5.7) | 8 (15.1) | 0 (0.0) | 1 (12.5) |
| Nurses | 25 (32.9) | 6 (26.1) | 19 (35.9) | 17 (32.1) | 8 (34.8) | 2 (8.0) |
| Nursing assistants | 15 (19.7) | 1 (4.4) | 14 (26.4) | 9 (16.9) | 6 (26.1) | 2 (13.3) |
| Others | 13 (17.1) | 4 (17.4) | 9 (17.0) | 8 (15.1) | 5 (21.7) | 2 (15.4) |
|
| ||||||
| Clinical specialties | 16 (21.1) | 3 (13.0) | 13 (24.5) | 7 (13.2) | 9 (39.1) | 2 (12.5) |
| Surgical specialties | 23 (30.3) | 10 (43.5) | 13 (24.5) | 19 (35.9) | 4 (17.4) | 3 (13.0) |
| Intensive care units | 8 (10.5) | 3 (13.0) | 5 (9.4) | 5 (9.4) | 3 (13.0) | 2 (25.0) |
| Emergencies | 7 (9.2) | 1 (4.4) | 6 (11.3) | 5 (9.4) | 2 (8.7) | 1 (14.3) |
| COVID hospitalization wards | 9 (11.8) | 1 (4.4) | 8 (15.1) | 7 (13.2) | 2 (8.7) | 1 (11.1) |
| Other services | 13 (17.1) | 5 (21.7) | 8 (15.1) | 10 (18.9) | 3 (13.0) | 2 (15.4) |
|
| ||||||
| Professional/Colleague at the hospital | 32 (42.1) | 10 (43.5) | 22 (41.5) | 25 (47.2) | 7 (30.4) | 4 (12.5) |
| Patients | 20 (26.3) | 7 (30.4) | 13 (24.5) | 13 (24.5) | 7 (30.4) | 4 (20.0) |
| Community contact | 12 (15.8) | 5 (21.7) | 7 (13.2) | 6 (11.3) | 6 (26.1) | 4 (33.3) |
|
| ||||||
| Reported cases in their setting after infection | 39 (51.3) | 10 (43.5) | 29 (54.7) | 25 (47.2) | 14 (60.9) | 8 (20.5) |
| Reported cohabiting cases in their setting after infection | 29 (38.2) | 8 (34.8) | 21 (39.6) | 19 (35.9) | 10 (43.5) | 8 (27.6) |
|
| ||||||
| Diabetes mellitus | 5 (6.6) | 1 (4.4) | 4 (7.8) | 1 (1.9) | 4 (17.4) * | 1 (20.0) |
| Hypertension | 8 (10.5) | 2 (8.7) | 6 (11.3) | 3 (5.7) | 5 (21.7) * | 2 (25.0) |
| Chronic lung disease | 5 (6.6) | 1 (4.4) | 4 (7.6) | 3 (5.7) | 2 (8.7) | 1 (20.0) |
| Allergic asthma | 8 (10.5) | 3 (13.0) | 5 (9.4) | 6 (11.3) | 2 (8.7) | 1 (12.5) |
| None | 63 (82.9) | 21 (91.3) | 42 (79.2) | 47 (88.7) | 16 (69.6) | 7 (11.1) |
|
| ||||||
| Fever < 38 °C | 59 (77.6) | 21 (91.3) | 38 (71.7) | 41 (77.4) | 18 (78.3) | 9 (15.3) |
| Fever > 38 °C | 34 (44.7) | 10 (43.5) | 24 (45.3) | 24 (45.3) | 10 (43.5) | 8 (23.5) |
| Upper respiratory tract symptoms | 67 (88.2) | 20 (87.0) | 47 (88.7) | 47 (88.7) | 20 (87.0) | 10 (14.9) |
| Cough | 47 (61.8) | 11 (47.8) | 36 (67.9) | 30 (56.6) | 17 (73.9) | 7 (14.9) |
| Throat pain | 24 (31.6) | 4 (17.4) | 20 (37.7) | 17 (32.1) | 7 (30.4) | 1 (4.2) |
| Sore throat | 34 (44.7) | 9 (39.1) | 25 (47.2) | 27 (50.9) | 7 (30.4) | 3 (8.8) |
| Choking | 15 (19.7) | 0 (0.0) | 15 (28.3) * | 11 (20.8) | 4 (17.4) | 2 (13.3) |
| Mucosal dryness | 43 (56.6) | 11 (47.8) | 32 (60.4) | 27 (50.9) | 16 (69.6) | 8 (18.6) |
| Rhinorrhoea | 36 (47.4) | 8 (34.8) | 28 (52.8) | 25 (47.2) | 11 (47.8) | 5 (13.9) |
| Otalgia | 3 (4.0) | 1 (4.4) | 2 (3.8) | 3 (5.7) | 0 (0.0) | 0 (0.0) |
| Headache | 48 (63.2) | 11 (47.8) | 37 (69.8) | 33 (62.3) | 15 (65.2) | 8 (16.7) |
| Periocular pain | 25 (32.9) | 6 (26.1) | 19 (35.9) | 16 (30.2) | 9 (39.1) | 4 (16.0) |
| Ageusia | 51 (67.1) | 16 (69.6) | 35 (66.0) | 34 (64.2) | 17 (73.9) | 7 (13.7) |
| Anosmia | 55 (72.4) | 17 (73.9) | 38 (71.7) | 38 (71.7) | 17 (73.9) | 8 (14.5) |
| Gastrointestinal symptoms | 45 (59.2) | 9 (39.1) * | 36 (67.9) * | 27 (50.9) | 18 (78.3) * | 9 (20.0) |
| Nausea | 17 (22.4) | 0 (0.0) | 17 (32.1) * | 10 (18.9) | 7 (30.4) | 4 (23.5) |
| Vomiting | 7 (9.2) | 0 (0.0) | 7 (13.2) | 4 (7.6) | 3 (13.0) | 2 (28.6) |
| Diarrhoea | 31 (40.8) | 5 (21.7) | 26 (49.1) * | 21 (39.6) | 10 (43.5) | 6 (19.4) |
| Abdominal pain | 21 (27.6) | 5 (21.7) | 16 (30.2) | 11 (20.8) | 10 (43.5) * | 3 (14.3) |
| Loss of appetite | 12 (15.8) | 2 (8.7) | 10 (18.8) | 6 (11.3) | 6 (26.1) | 2 (16.6) |
| Fatigue | 64 (84.2) | 21 (91.3) | 43 (81.1) | 43 (81.1) | 21 (91.3) | 10 (15.6) |
| Arthromyalgia | 56 (73.7) | 17 (73.9) | 39 (73.6) | 39 (73.6) | 17 (73.9) | 8 (14.3) |
| Generalized AM | 14 (18.4) | 7 (30.4) | 7 (13.2) | 10 (18.9) | 4 (17.4) | 1 (7.1) |
| Upper limb myalgia | 11 (14.5) | 3 (13.0) | 8 (15.1) | 7 (13.2) | 4 (17.4) | 1 (9.1) |
| Lower limb myalgia | 17 (22.4) | 2 (8.7) | 15 (28.3) | 12 (22.6) | 5 (21.7) | 2 (11.8) |
| Back myalgia | 21 (27.6) | 7 (30.4) | 14 (26.4) | 17 (32.1) | 4 (17.4) | 4 (19.0) |
| Dyspnoea | 30 (39.5) | 9 (39.1) | 21 (39.6) | 21 (39.6) | 9 (39.1) | 8 (26.7) |
| Rib pain | 24 (31.6) | 4 (17.4) | 20 (37.7) | 13 (24.5) | 11 (47.9) * | 5 (20.8) |
| Dermatological symptoms | 11 (14.5) | 4 (17.4) | 7 (13.2) | 7 (13.2) | 4 (17.4) | 1 (9.1) |
* p < 0.05. 1 In parentheses, the proportion of hospitalized professionals in each category of baseline variables.
Figure 1Most frequent symptoms and most relevant temporal outcomes in healthcare professionals with COVID-19.
Preventive behaviours prior to the COVID-19 pandemic and main concerns of health professionals during SARS-CoV-2 infection.
| Variable | Total | Males | Females | |
|---|---|---|---|---|
|
| ||||
| Adequate hand hygiene (yes/no) (n, %) | 63 (82.9) | 18 (81.8) | 45 (84.9) | 0.740 |
| Hand hygiene (self-score 1–10) (mean, sd) | 7.4 (2.3) | 7.0 (0.5) | 7.6 (0.3) | 0.354 |
| Self-use of masks (n, %) | 16 (21.1) | 1 (4.55) | 15 (28.3) | 0.022 |
| Use of masks for patients (n, %) | 12 (15.8) | 3 (14.3) | 9 (17.0) | 0.777 |
|
| ||||
| Spreading the disease in the environment (n, %) | 34 (44.7) | 11 (47.8) | 23 (43.4) | 0.721 |
| Clinical deterioration or sequelae (n, %) | 27 (35.5) | 9 (39.1) | 18 (34.0) | 0.665 |
| Psychological effects and loneliness of confinement (n, %) | 6 (7.9) | 1 (4.4) | 5 (9.4) | 0.450 |
| Concerns about returning to work (n, %) | 3 (4.0) | 1 (4.4) | 2 (3.8) | 0.906 |
Median times for the main outcomes.
| Time-to-Outcome Intervals | Total Sample | Stratified for Sex | Stratified for Age | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Males | Females | Age <55 Years | Age ≥55 Years | |||||||
| Outcomes | Censored | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | ||||
| Date of perceived risk contact to Start of symptoms 2 | 39 | 39 | 0 | 4 (3, 7) | 5 (3, 7) | 4 (2, 7) | 0.387 | 5 (3, 7) | 4 (2, 5) | 0.125 |
| Start of symptoms to End of symptoms | 76 | 55 | 21 | 14 (10, -) | 13 (8, 17) | 17 (11, -) | 0.024 | 14 (10, 22) | 19 (11, -) | 0.129 |
| Start of symptoms to First positive PCR 3 | 76 | 76 | 0 | 2 (1, 5) | 2 (1, 4) | 3 (1, 5) | 0.081 | 2 (1, 4) | 3 (1, 6) | 0.784 |
| Start of symptoms to Negative PCR | 76 | 44 | 32 | 31 (21, -) | 21 (18, -) | 33 (25, -) | 0.025 | 28 (10, 39) | 33 (25, -) | 0.207 |
| First positive PCR to Negative PCR | 76 | 44 | 32 | 25 (18, 37) | 19 (16, -) | 30 (22, 37) | 0.076 | 22 (17, 37) | 31 (23, -) | 0.119 |
| End of symptoms to Negative PCR 4 | 53 | 33 | 20 | 15 (9, 25) | 10 (8, 16) | 17 (12, 24) | 0.322 | 13 (8, 24) | 18 (14, 26) | 0.522 |
The upper limit (p75%) of the IQR could not be obtained in some groups due to censoring. 1 p-values assess differences in the hazard ratio of each outcome across age and sex groups, obtained from the corresponding Cox regression model including age and sex as covariates. 2 For this outcome, 37 patients could not recall any risk contact. 3 We assigned a value of 0.5 days in 10 patients who reported that symptom onset and their first positive PCR result occurred on the same day. 4 Of 55 patients with a date for end of symptoms (not censored for this outcome), one had a negative PCR result 4 days before the date of end of symptoms, and another had a negative PCR result the same date as the end of symptoms; both patients were excluded from this analysis.
Figure 2Kaplan–Meier survival analysis curves for negative PCR outcome. (a) Days from end of symptoms. (b) Days from first positive PCR. Shaded area: 95% confidence interval.